Heavy Bleeding at 51: Is It Time to Biopsy Before the Periods Stop?

Yes - endometrial sampling is indicated. The pivotal fact is her age: any woman aged 45 or older with abnormal uterine bleeding warrants endometrial evaluation, regardless of bleeding pattern, ultrasound findings, or menopausal status. She is 51, still cycling, so this is not postmenopausal bleeding (defined as bleeding more than 12 months after the last menstrual period) - but the age threshold applies to her all the same. "Still having periods" does not defer the biopsy.

Her additional risk factors compound the indication:

• BMI 34 - peripheral conversion of androgens to oestrone produces unopposed oestrogen
• Type 2 diabetes (HbA1c 7.4%) - classic for endometrial hyperplasia and carcinoma
• Family history of endometrial cancer in a first-degree relative
• Nulliparity
• Chronic anovulation suggested by the irregular 21–45 day cycle

Why her proposal is inadequate. Removing the copper IUD is sensible for bleeding control, but the device is not the cause of the irregularity, and removal does not address the endometrial risk. Iron alone treats the anaemia - which is real, at Hb 9.4 g/dL and ferritin 8 ng/mL - and nothing else. Waiting until her periods stop means waiting months to years with an undiagnosed endometrium in a woman with multiple risk factors.

What to say. Frame the biopsy as a five-minute office procedure with cramping comparable to a period, and be explicit that the purpose is to exclude cancer, not because you assume she has it. Address her fear directly rather than moving straight to the procedure list.

Tissue first. Office endometrial biopsy (pipelle) is the primary test and can be done at this visit. It detects about 90% of endometrial cancers, with the main false-negative risk being an inadequate sample or a focal lesion. If the sample is inadequate or the result is benign but bleeding persists, proceed to hysteroscopy with directed biopsy - do not repeat pipelle indefinitely.

Imaging. Transvaginal ultrasound is useful but for the wrong question in her case. Its strength is measuring endometrial thickness to triage postmenopausal bleeding (a thin, uniform endometrium has a very high negative predictive value). In a premenopausal, still-cycling woman, endometrial thickness changes through the cycle, so a single measurement is not a reliable cancer triage tool. Use ultrasound instead to assess myometrial and structural pathology: fibroids, adenomyosis, retained IUD position, and ovarian pathology. Saline infusion sonohysterography or hysteroscopy is needed if a cavity lesion is suspected.

Additional tests:

• Repeat full blood count and ferritin after treatment to track the anaemia
• Coagulation studies only if bleeding is suggestive - not routine at 51
• Cervical screening is overdue for its interval: she needs HPV-based screening or co-testing, and a Pap alone 4 years ago does not satisfy current guidance
• Recheck HbA1c and review diabetes control, since it directly affects endometrial risk

The pattern of ordering matters: biopsy answers "is this cancer?", ultrasound answers "is there a structural cause?", and blood tests answer "how much has she lost?" Order all three, but do not let a reassuring ultrasound stop the biopsy.

Step 1 - Remove the copper IUD. It is a modifiable contributor to heavy menses (copper devices increase menstrual flow). Do this once the biopsy is taken so the sample is not confused by procedure-related bleeding.

Step 2 - Treat the anaemia. Hb 9.4 g/dL with ferritin 8 ng/mL is iron deficiency anaemia. Offer oral ferrous sulfate with vitamin C, but given the ferritin and the ongoing losses, discuss intravenous iron - faster correction, better tolerated, and appropriate for a woman who is actively bleeding. Recheck in 4–6 weeks.

Step 3 - Control the bleeding.

• LNG-IUD (52 mg) is first-line for heavy menstrual bleeding in a woman with a structurally normal uterus: it reduces loss by around 70–90%, gives contraception, and protects the endometrium. She is nulliparous - counsel about insertion discomfort and offer misoprostol or a paracervical block. Insert it after the biopsy result, not before, so the sample is not compromised.
• Tranexamic acid 1 g three times daily on the heaviest days only, non-hormonal and compatible with her preferences; avoid if there is a history of thrombosis.
• NSAIDs reduce loss modestly but may aggravate gastritis - use with care alongside iron.
• Combined hormonal contraception or cyclical progestogen if she prefers a systemic option and has no contraindications (BMI 34 and diabetes raise thrombotic risk with oestrogen - assess carefully).

Step 4 - Escalate according to histology.

• Proliferation without atypia: LNG-IUD and repeat sampling in 3–6 months
• Atypia or carcinoma: refer to gynaecological oncology promptly - do not manage with a device
• Fibroids or adenomyosis as the dominant cause: hysteroscopic myomectomy, uterine artery embolisation, or endometrial ablation (she must accept that ablation is not contraception)

Step 5 - Shared decision-making. She has said she wants to avoid hysterectomy, and her fertility wishes are not relevant at 51 but her uterus is. Document that alternatives were offered, that ablation and embolisation spare the uterus, and that hysterectomy remains a fallback if bleeding is uncontrolled or atypia is found. Book a review to close the loop on the biopsy and the ferritin.